Visinin-like protein 1 (VILIP-1)

Visinin-like protein 1 (VILIP-1)

> VILIP-1 as neuronal secretion biomarker in Alzheimer's disease: clinical utility, mechanisms, and comparison with other neurodegeneration markers

Overview

Visinin-like protein 1 (VILIP-1, encoded by VSNL1 gene) is a neuronal calcium sensor protein belonging to the neuronal calcium sensor (NCS) family. Originally identified as a protein expressed in vertebrate retina, VILIP-1 is abundantly expressed in neurons throughout the brain, particularly in cortex and hippocampus, and is secreted into cerebrospinal fluid as a marker of neuronal dysfunction. VILIP-1 was among the first neuronal secretion biomarkers proposed for Alzheimer's disease, with early studies demonstrating its ability to predict cognitive decline and track disease progression[@mandler_vilip].

Unlike synaptic markers like [SNAP-25](/biomarkers/snap25) which reflect synaptic terminal integrity, VILIP-1 provides a broader indicator of neuronal health and calcium signaling dysfunction, complementing other neurodegeneration markers. CSF VILIP-1 is elevated in Alzheimer's disease, Parkinson's disease dementia, and other neurodegenerative conditions, with levels correlating with cognitive impairment and disease severity[@tarawneh_vilip].

Biochemistry

VILIP-1 Protein Structure

VILIP-1 is a 191-amino acid protein (approximately 22 kDa) with features typical of the neuronal calcium sensor family[@lee_vilip]:

Visinin-like protein 1 (VILIP-1)

> VILIP-1 as neuronal secretion biomarker in Alzheimer's disease: clinical utility, mechanisms, and comparison with other neurodegeneration markers

Overview

Visinin-like protein 1 (VILIP-1, encoded by VSNL1 gene) is a neuronal calcium sensor protein belonging to the neuronal calcium sensor (NCS) family. Originally identified as a protein expressed in vertebrate retina, VILIP-1 is abundantly expressed in neurons throughout the brain, particularly in cortex and hippocampus, and is secreted into cerebrospinal fluid as a marker of neuronal dysfunction. VILIP-1 was among the first neuronal secretion biomarkers proposed for Alzheimer's disease, with early studies demonstrating its ability to predict cognitive decline and track disease progression[@mandler_vilip].

Unlike synaptic markers like [SNAP-25](/biomarkers/snap25) which reflect synaptic terminal integrity, VILIP-1 provides a broader indicator of neuronal health and calcium signaling dysfunction, complementing other neurodegeneration markers. CSF VILIP-1 is elevated in Alzheimer's disease, Parkinson's disease dementia, and other neurodegenerative conditions, with levels correlating with cognitive impairment and disease severity[@tarawneh_vilip].

Biochemistry

VILIP-1 Protein Structure

VILIP-1 is a 191-amino acid protein (approximately 22 kDa) with features typical of the neuronal calcium sensor family[@lee_vilip]:

Structural features:

• N-terminal variable region — Contains myristoylation site for membrane targeting
• EF-hand motifs — Four canonical EF-hand calcium-binding domains
• C-terminal region — Regulates protein-protein interactions

The EF-hand domains undergo conformational changes upon calcium binding, enabling VILIP-1 to interact with downstream effector proteins in a calcium-dependent manner.

VILIP Protein Family

The VILIP family comprises four members[@petrus_vilip]:

| Protein | Gene | Expression | Notes |
|---------|------|------------|-------|
| VILIP-1 | VSNL1 | Brain (neurons) | Most studied in neurodegeneration |
| VILIP-2 | VSNL2 | Brain, retina | Similar structure |
| VILIP-3 | VSNL3 | Brain, endocrine | Least studied |
| hippocalcin | HPCA | Brain (hippocampus) | Closely related |

VILIP-1, VILIP-2, and VILIP-3 share 50-60% sequence homology and have overlapping but distinct expression patterns.

Cellular Localization and Trafficking

VILIP-1 localization[@bernstein_vilip]:

• Cytosolic — Primary location in resting neurons
• Membrane-associated — Via N-terminal myristoylation upon calcium binding
• Secretory pathway — Present in secretory granules
• Extracellular — Released upon neuronal activity or injury

Pathophysiological Role

Calcium Dysregulation in Neurodegeneration

VILIP-1 is a direct indicator of neuronal calcium dysregulation, a central pathogenic mechanism in AD[@lee_vilip]:

Calcium hypothesis of AD:

• Amyloid-beta and tau pathology disrupt neuronal calcium homeostasis
• Excessive calcium influx through voltage-gated channels and NMDA receptors
• Mitochondrial calcium overload leads to oxidative stress
• Calcium-dependent enzymes (calpains, kinases) become dysregulated
• VILIP-1 release reflects this calcium dysregulation

VILIP-1 in Specific Diseases

Alzheimer's Disease[@tarawneh_vilip]:

VILIP-1 elevation in AD reflects the widespread neuronal dysfunction:

• Correlates with severity of cognitive impairment
• Predicts conversion from MCI to AD dementia
• Independent of amyloid-beta burden
• Provides information complementary to tau and synaptic biomarkers

In synucleinopathies, VILIP-1 reflects cortical neuronal involvement:

• Elevated in PD dementia more than early PD
• Correlates with cognitive decline severity
• May distinguish PD from DLB (different patterns)

VILIP-1 in DLB:

• Elevated in DLB with AD co-pathology
• May differentiate pure DLB from DLB with AD features
• Complements alpha-synuclein biomarkers

VILIP-1 vs SNAP-25

These neuronal biomarkers provide different but complementary information[@brendel_vilip]:

| Feature | VILIP-1 | SNAP-25 |
|---------|---------|---------|
| Primary source | Neuronal soma and dendrites | Synaptic terminals |
| Release mechanism | Calcium dysregulation, activity | Synaptic dysfunction |
| AD sensitivity | High | High |
| Specificity | Neuronal injury | Synaptic loss |
| Correlation with tau | Moderate | Independent |
| Correlation with NfL | Moderate | Low |

Clinical Utility

Diagnostic Performance

CSF VILIP-1 in Alzheimer's disease[@galasko_vilip]:

| Comparison | AUC | Notes |
|------------|-----|-------|
| AD vs CN | 0.82-0.88 | Good accuracy |
| AD vs FTD | 0.75-0.82 | Moderate |
| MCI-AD vs stable MCI | 0.78-0.84 | Good predictive value |
| AD vs DLB | 0.72-0.78 | Limited |

VILIP-1 performs well but is less accurate than core AD biomarkers (p-tau181, p-tau217) and is best used as a complementary marker rather than standalone diagnostic.

Prediction of Cognitive Decline

VILIP-1 is a strong predictor of cognitive decline[@rosso_vilip]:

MCI to AD conversion:

• Higher baseline VILIP-1 predicts faster progression
• Rate of VILIP-1 increase correlates with decline rate
• Independent of baseline cognition and amyloid status

• VILIP-1 increases over time in AD
• Rate of increase associated with clinical deterioration
• Levels plateau in advanced disease stages

Disease Progression

VILIP-1 tracks disease severity[@bjerke_vilip]:

• Correlates with MMSE and other cognitive scores
• Associates with regional brain atrophy (especially hippocampus)
• May indicate neuronal loss severity
• Combined with tau markers provides comprehensive staging

Biomarker Panel Integration

Combinations with Core Biomarkers

VILIP-1 complements core AD biomarkers[@brendel_vilip]:

VILIP-1 + p-tau181:

• Provides neuronal dysfunction + tau pathology information
• Together cover two major AD pathophysiological axes
• Improved diagnostic accuracy when combined

• Covers both calcium signaling (VILIP-1) and synaptic integrity (SNAP-25)
• Detects different aspects of neuronal dysfunction
• May be particularly useful in PD and DLB

• [GFAP](/biomarkers/gfap) — Astrocyte activation
• [p-tau181](/biomarkers/csf-pta181) or [p-tau217](/biomarkers/csf-pta217) — Tau pathology
• VILIP-1 or SNAP-25 — Neuronal/synaptic dysfunction
• [NfL](/biomarkers/neurofilament-light) — Axonal degeneration

Diagnostic Algorithm

VILIP-1 in differential diagnosis[@irwin_vilip]:

| Diagnosis | VILIP-1 | Other markers | Interpretation |
|-----------|---------|---------------|----------------|
| AD dementia | Elevated | A+T+ | Confirmed AD with neuronal injury |
| AD-MCI | Elevated | A+T+ | Prodromal AD |
| DLB (AD+) | Elevated | A+T+SNAP-25+ | Mixed pathology |
| DLB (pure) | Normal/Low | A-N+SNAP-25+ | Pure DLB |
| FTD | Normal/Low | A-T- | Non-AD pathophysiology |

Analytical Methods

Immunoassays

CSF VILIP-1 is measured using validated ELISA platforms[@mandler_vilip]:

| Platform | Detection Range | Notes |
|----------|-----------------|-------|
| ELISA (research) | 50-2000 pg/mL | Most commonly used |
| MSD | 10-1000 pg/mL | Higher sensitivity |
| Simoa | 1-100 pg/mL | Research use |

Pre-analytical Considerations

CSF VILIP-1 measurement:

• Standard lumbar puncture collection
• Centrifugation and aliquoting within 2 hours
• Storage at -80°C for long-term stability
• Minimal degradation with freeze-thaw cycles

Cutoff Values

CSF VILIP-1 concentrations (ELISA):

| Concentration | Interpretation | Clinical Context |
|--------------|----------------|-----------------|
| <150 pg/mL | Normal | Cognitively unimpaired |
| 150-250 pg/mL | Borderline | Requires clinical correlation |
| >250 pg/mL | Elevated | Consistent with neuronal injury |

Age and cohort-specific cutoffs should be established locally due to platform variability.

Limitations

Technical Limitations

• Assay standardization — Limited compared to core AD biomarkers
• Commercial availability — Not as widely available as p-tau, NfL assays
• Cross-reactivity — Potential cross-reactivity with other VILIP family members

Clinical Limitations

• Non-specific — Elevated in multiple neurodegenerative conditions
• Diagnostic accuracy — Lower than p-tau181/p-tau217 for AD
• Not AD-defining — Requires amyloid confirmation for AD diagnosis
• Mechanistic ambiguity — Cannot distinguish between calcium dysregulation, synaptic dysfunction, and cell death

Confounding Factors

| Factor | Effect | Notes |
|--------|--------|-------|
| Age | Modest increase with aging | Age-adjusted cutoffs |
| Traumatic brain injury | Acute elevation | Recent TBI elevates VILIP-1 |
| Stroke | Acute elevation | Recent stroke confounds |
| Seizures | Activity-dependent elevation | Recent seizures affect levels |

Research Applications

Calcium Dysregulation Monitoring

VILIP-1 provides a window into calcium signaling dysfunction[@lee_vilip]:

• Direct indicator of disturbed neuronal calcium homeostasis
• Correlates with calpain activation and other calcium-dependent processes
• May reveal treatment effects on calcium homeostasis targets

Therapeutic Target Engagement

In clinical trials targeting calcium channels or calcium-dependent pathways:

• VILIP-1 as pharmacodynamic marker
• Demonstrates effects on neuronal calcium signaling
• May predict clinical outcomes based on calcium pathway modification

Multimodal Integration

VILIP-1 combined with imaging and other biomarkers[@wolf_vilip]:

• Correlates with FDG-PET hypometabolism patterns
• Associated with specific Braak stages
• Provides mechanistic context to imaging findings

Summary

VILIP-1 is a validated CSF biomarker that reflects neuronal calcium dysregulation and dysfunction in Alzheimer's disease and other neurodegenerative conditions. Key points:

• Biochemistry: Neuronal calcium sensor protein, 191 aa, EF-hand domains, calcium-dependent secretion
• Clinical performance: AUC 0.82-0.88 for AD vs CN; good predictor of MCI-AD progression
• Cutoff values: CSF >250 pg/mL indicates elevated neuronal injury
• Clinical utility: Cognitive decline prediction, disease progression monitoring, complementary biomarker
• Strengths: Direct neuronal marker, calcium dysregulation indicator, independent of amyloid/tau
• Limitations: Less accurate than p-tau biomarkers, non-specific, limited availability

Related Biomarkers

• [SNAP-25](/biomarkers/snap25) — Synaptic terminal marker; complementary to VILIP-1
• [Neurofilament Light Chain (NfL)](/biomarkers/neurofilament-light) — Axonal degeneration marker
• [Phosphorylated Tau 181 (p-tau181)](/biomarkers/csf-pta181) — Tau pathology; combined with VILIP-1
• [Calcium Dysregulation in Alzheimer's Disease](/mechanisms/calcium-dysregulation-alzheimers) — Mechanism page
• [Neuronal Calcium Sensor Proteins](/entities/vsnl1) — VILIP-1 gene page

References